Tradestie Institutional Equity Comparison Engine

AKRO vs LFCR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKRO Overall Edge

AKRO Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical while LFCR counters with relative strength in Valuation, Options & Structure. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LFCR at 8.7x Forward P/E and -6.2% operating margin (-18.6% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against LFCR sits in CONSOLIDATION (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LFCR
AKRO N/M vs LFCR 8.7x Fwd P/E
Growth & Margin Winner AKRO
Op Margin 0.0% vs -6.2% ยท YoY +0.0% vs -18.6%
Momentum & Technical Winner AKRO
1Y +76.8% vs -14.7% ยท 52W Pos 90% vs 52%
Options & Structure Winner LFCR
UNCLASSIFIED (30th %ile IV) vs CONSOLIDATION (<1st %ile IV)
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
LFCR NASDAQ
Lifecore Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$6.39
+0.31% 1D
Market Cap $241.5M
1M Return +0.31%
1Y Return -14.69%
Forward P/E 8.7x
Unified AI Score
58.2 / 100 HOLD
Tech 52.0 Fund 55.0 Flow 62.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKRO +76.75% LFCR -14.69% Spread: +0.3 pp (AKRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKRO TTM Op. Margin: 0.0% LFCR TTM Op. Margin: -6.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs LFCR. Trailing 12-month operating profitability (AKRO 0.0% vs LFCR -6.2%) and valuation multiples (AKRO N/M vs LFCR 8.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKRO (8) vs LFCR (2)
Institutional Metric AKRO LFCR Criterion Row Winner
Market Capitalization Scale $4.5B $241.5M Larger Scale AKRO
Trailing P/E Ratio Valuation N/M 8.7x Lower Multiple LFCR
Forward P/E Ratio Valuation N/M 8.7x Lower Multiple LFCR
Revenue Growth (YoY) Growth +0.0% -18.6% Higher Growth AKRO
Operating Margin (TTM) Profitability 0.0% -6.2% Higher Margin AKRO
Net Profit Margin Profitability 0.0% -66.8% Higher Margin AKRO
Return on Equity (ROE) Capital Efficiency -34.5% -76.4% Higher ROE AKRO
52-Week Range Position Momentum 90% ($21โ€“$58) 52% ($4โ€“$9) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.90ฮฒ ยท 2% Vol 0.44ฮฒ ยท 9% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 60.0 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKRO vs LFCR Buy Guide
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LFCR CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LFCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKRO nor LFCR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.